RxDoctor Payments Data

Shahab Mohiuddin, MD

Internal Medicine · Dedham, MANPI 1447225834

Payments from drug & device makers

$871in general payments, 2019–2025

Across 31 payments — averaging $28.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$178
  • Lilly USA, LLC$175
  • Johnson & Johnson$111
  • Novo Nordisk$103
  • Novartis$85
  • Pfizer$61
  • plus $158 from 4 others

What the payments were for

  • Food & beverage$871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$871 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$72,700
Medicare patients
226
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$82,068
TrulicityDulaglutide64$74,720
JardianceEmpagliflozin60$74,530
JanuviaSitagliptin Phosphate22$25,855
MyrbetriqMirabegron28$18,546
OzempicSemaglutide18$17,454
XareltoRivaroxaban18$16,993
LinzessLinaclotide17$13,332
AciphexRabeprazole Sodium13$10,940
FarxigaDapagliflozin Propanediol15$10,208
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,605
Atorvastatin Calcium531$6,094
Omeprazole316$4,576
Metoprolol Succinate156$3,462
Esomeprazole Magnesium39$3,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$82,06889 claims
Lilly USA, LLCTrulicity$175$74,72064 claims
Astellas Pharma US IncMyrbetriq$40$18,54628 claims
Novo NordiskOzempic$103$17,45418 claims
Johnson & JohnsonXarelto$111$16,99318 claims
AbbVieLinzess$39$13,33217 claims
AstraZenecaFarxiga$36$10,20815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Dedham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →